Sue Hughes October 12, 2023 Two new studies of the potential neuroprotective agent nerinetide (NoNO Inc) for patients with acute ischemic stroke have shown conflicting but intriguing results. While the phase 3 ESCAPE-NEXT trial failed to show a benefit of nerinetide for stroke patients undergoing endovascular therapy, when the drug was given an average of 4 to...